Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Metformin in Refractory MSS Metastatic Colorectal Cancer
NCT03800602Phase 2Completed
- Sponsor
- Emory University
- Start
- Jan 2019
- Primary completion
- Sep 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in colorectal cancer (CRC), sponsored by Emory University. Primary endpoint: Overall Response Rate up to 1 year. Started Jan 2019; status: completed.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03800602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03800602.